NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Core Insights - NewAmsterdam Pharma is presenting new clinical and preclinical data on obicetrapib, an oral, low-dose therapy for hypercholesterolemia, at the European Atherosclerosis Society Congress in May 2025 [1] - The company aims to address the unmet need for effective LDL-C lowering therapies for patients at risk of cardiovascular disease [4] Clinical Trial Presentations - A Phase 3 randomized trial on the fixed-dose combination of obicetrapib and ezetimibe for LDL-C reduction will be presented on May 5, 2025 [2] - Safety and efficacy data of obicetrapib in high cardiovascular risk patients will also be discussed on the same day [2] Additional Session Details - Obicetrapib's effects on atherosclerosis and vascular inflammation will be presented, highlighting its role in reducing non-HDL cholesterol and improving lesion stability [3] - The therapy's impact on reverse cholesterol transport and its safety in combination with moderate-dose statins will be showcased in various sessions [3] Company Overview - NewAmsterdam Pharma focuses on developing oral, non-statin medicines for patients with elevated LDL-C, aiming to improve patient care in populations with metabolic diseases [4] - The company is conducting multiple Phase 3 trials to investigate obicetrapib as a CETP inhibitor, both alone and in combination with ezetimibe [4]